Pharmac committed to stronger, more inclusive consumer relationships

Source: PHARMAC

Pharmac Board Chair Paula Bennett is welcoming an independent report calling for stronger, more respectful relationships with consumers to ensure their voices are listened to and included in the organisation’s work.

The report was prepared for the Board following two workshops with advocacy groups representing people with lived experience of health conditions. The Board commissioned the workshops, which were independently chaired by Dame Kerry Prendergast in Wellington last November.

“I want to really thank the people who took part in the workshops and generously shared their personal experiences and insights into working with Pharmac,” says Bennett. 

Workshop participants identified a number of areas where Pharmac needs to improve the way it engages, communicates and works with consumer groups and advocates. This included better decision-making processes, meaningful and respectful engagement, and effective and transparent communications. 

“We’ve heard very clearly that we need to make sure our interactions are respectful and meaningful, and that people’s voices are valued and included throughout our work,” Bennett says. 

“There’s a lot for the Board and Pharmac’s senior management to think about, and we’re considering the next steps. This work is part of a wider reset for Pharmac to become an outward-focused organisation. The team at Pharmac does an amazing job and we’re committed to meaningful change to strengthen Pharmac’s relationships with consumers.”

She says the Board has proactively released the report of the workshops to demonstrate the organisation’s commitment to change and being transparent.

Agenda for May 2025 Pharmacology and Therapeutics Advisory Committee (PTAC) meeting

Source: PHARMAC

Information on what the Pharmacology and Therapeutics Advisory Committee (PTAC) will be considering at its meeting in May 2025.

Applications

Foslevodopa / foscarbidopa for advanced Parkinson disease

The Committee will discuss an application for a new treatment for advanced Parkinson disease for people experiencing severe motor fluctuations despite optimal treatment with other medicines. Parkinson disease is one of the most common neurological (brain and nervous system) conditions. It affects movement and coordination.

Foslevodopa / foscarbidopa (branded as Vyalev) is administered using a portable pump to provide a continuous subcutaneous infusion.

Application for foslevodopa / foscarbidopa for Parkinson disease(external link)

Etonogestrel (Implanon NXT) subdermal implant for contraception

The Committee will discuss a new application for a contraceptive implant (Implanon NXT) used to prevent pregnancy. Implanon NXT is a type of long-acting reversible contraceptive (LARC) method. The implant is a single rod that slowly releases the hormone etonogestrel. It is inserted under the skin of the upper arm.

Application for etonogestrel (Implanon Nxt) implant for contraception(external link)

Vanzacaftor, tezacaftor, deutivacaftor for cystic fibrosis

The Committee will discuss a new treatment for people with cystic fibrosis – vanzacaftor, tezacaftor, deutivacaftor (branded as Alyftrek). Cystic fibrosis is an inherited life-long genetic condition affecting the lungs, liver, digestive system, and other parts of the body.

This application considers treatment in people with cystic fibrosis (aged 6 years and older) with F508del mutation(s) or another treatment responsive mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. This treatment is a once daily option.

Application for vanzacaftor, tezacaftor, deutivacaftor for cystic fibrosis(external link)

Secukinumab for a severe skin condition

The Committee will discuss a new application for secukinumab (branded as Cosentyx) to treat people with moderate to severe hidradenitis suppurativa. Hidradenitis suppurativa is a long-term inflammatory skin condition that causes painful lumps under the skin, typically in areas like the armpits and groin.

The Committee will consider the use of secukinumab as first-line biologic treatment and second-line biologic treatment.  

Application for secukinumab for hidradenitis suppurativa(external link)

Sacituzumab govitecan for breast cancer

The Committee will discuss a new application for sacituzumab govitecan (branded as Trodelvy) for people with triple negative, locally advanced or metastatic breast cancer.  Triple-negative breast cancer is a type of breast cancer that does not have receptors for oestrogen, progesterone or HER2.

The Committee will consider treatment in the third-line setting (after two or more prior treatments).

Application for sacituzumab govitecan for triple negative, locally advanced or metastatic breast cancer(external link)

Durvalumab for the treatment of lung cancer

The Committee will discuss a new application for durvalumab (branded as Imfinzi) to treat people with extensive-stage small cell lung cancer (ES-SCLC). It is used in combination with etoposide and either carboplatin or cisplatin. ES-SCLC is when the cancer has spread widely within the lungs or to other parts of the body.

Application for durvalumab for extensive-stage small cell lung cancer(external link)

Advisory meeting agenda setting

The scheduling and agenda setting process for advisory meetings considers multiple factors. We aim to balance the relative priorities of:

  • clinical advice needed across indications
  • the factors for consideration for each application (such as, unmet health need)
  • the time since applications were received
  • the internal and advisor resource available to support each meeting.

More about PTAC

Pharmac’s plans to improve access to asthma inhalers

Source: PHARMAC

Pharmac is seeking feedback on a proposal to make it easier for people with asthma to access a type of inhaler.

“We’re proposing two changes, which would make it easier for 120,000 New Zealanders with asthma to access the inhalers they need,” says Pharmac’s Director Pharmaceuticals, Geraldine MacGibbon.

Pharmac is proposing to apply three-monthly (all at once) dispensing to certain types of budesonide with eformoterol inhalers. Currently these inhalers are available on prescription, with people required to collect their treatment every month. 

If approved, people would be able to receive three months of supply at a time.

“People won’t have to return to their pharmacy multiple times collect repeats for their inhalers. It would save time for New Zealanders and mean that people could have more than one inhaler at a time and store them where they are mostly likely to need them,” MacGibbon says.

Pharmac is also proposing a change which would provide further support for New Zealanders moving onto these inhalers.

“We’re proposing to make these inhalers available in health care clinics on a Practitioners Supply Order (PSO). This would mean that people who are starting their treatment can learn how to use this inhaler during their health appointment.

“This change is intended to make it easier for people to learn how to use their budesonide with eformoterol inhalers, which would lead to better management of their asthma,” MacGibbon says.  

She says the changes being proposed align with the asthma treatment guidelines and would have a positive impact for hundreds of thousands of New Zealanders living with asthma.

“These changes would give people with asthma more flexibility in accessing the inhalers they need, and ensure people learn how to use them correctly” MacGibbon says.  

The Government provided additional funding to Pharmac in June 2024 to fund new medicines and widen access to medicines that are already funded

Consultation opens today and closes at 4pm Friday 9 May 2025. Feedback can be emailed to consult@pharmac.govt.nz or submitted using our online form

Pharmac to fund medicines for blood cancers, inflammatory bowel disease, eczema and arthritis

Source: PHARMAC

More New Zealanders will have access to medicines for blood cancers, bowel diseases, eczema and arthritis, following Pharmac’s decision to widen access to four medicines for six health conditions from 1 May 2025.

The medicines and health conditions are:

  • venetoclax (brand name Venclexta) in combination with azacitidine or cytarabine for a type of blood cancer called acute myeloid leukaemia
  • azacitidine (brand name Azacitidine Dr Reddy’s) for acute myeloid leukaemia
  • ibrutinib (brand name Imbruvica) for chronic lymphocytic leukaemia
  • upadacitinib (brand name Rinvoq) for atopic dermatitis (eczema), ulcerative colitis, Crohn disease, and rheumatoid arthritis.

Pharmac currently funds venetoclax for a different type of blood cancer called chronic lymphocytic leukaemia, and funds upadacitinib for some people with rheumatoid arthritis. Azacitidine is currently funded for other types of blood cancer.

“We’re making these treatments available for more people. We estimate that 1200 New Zealanders will benefit from widened access to these medicines in the first year of funding, with 5,070 people benefiting per year after five years” says Pharmac’s Chief Medical Officer, Dr David Hughes.

“Widening access to these medicines will have a huge impact on the people who need them, but will also have benefits for the wider health system,” Hughes says.

Widened access to upadacitinib will reduce the need for Health NZ infusion services, reducing infusion times by 4,000 hours in the first year of funding.

Hughes says Pharmac have widened access to these medicines through a bundle agreement with the supplier, AbbVie.

“Our team have negotiated a great deal with AbbVie. Alongside making venetoclax and upadacitinib available to more New Zealanders at a reduced net price, our teams have also negotiated price reductions for two already funded medicines – a medicine used to treat Hepatitis C, and a medicine to treat inflammatory conditions.

“These savings enable us to maximise the use of our medicines budget to fund more treatments for New Zealanders,” says Hughes.  

Pharmac has made several changes in response to feedback received from clinicians, patient support and advocacy groups and patients, including changing the access criteria so that people privately funding these medicines can transition to publicly funded treatment, provided the same eligibility criteria were met prior to starting treatment.

“I want to thank everyone who took the time to provide us with feedback during our consultation. Your views are important to us and affect our decisions,” Hughes says.

Pharmac can consider widening access to these medicines following the Government’s $604 million medicine budget increase in June 2024.

Questions and answers

21,000 would benefit from proposed changes to New Zealanders access to contraceptives

Source: PHARMAC

Pharmac is consulting on a proposal that would make it easier for thousands of New Zealanders to access contraceptives.

Pharmac’s Clinical Lead – Medicines Management, Melissa Copland, says that the changes would improve access, and remove barriers for people who use IUDs.

“The changes we are proposing would mean people would be able to get Mirena and Jaydess IUDs directly from their doctor or nurse, during their appointment.

“Under the current system, people need to get a prescription, pick their IUD up from a pharmacy, and then bring it back to the clinic to get it placed.

“We know that this extra step can lead to delays and barriers to accessing IUDs for some people.

“Funding the Mirena and Jaydess IUDs on the Practitioners Supply Order (PSO) list will make it faster and easier for New Zealanders to access these IUDs and make access consistent with other long-acting contraceptives.”

The Practitioners Supply Order (PSO) list allows health care practitioners to get funded medicines for use in their clinics. Pharmac is also proposing to increase the number of Jadelle contraceptive implants that clinics can order on PSO.

“We have been told that some clinics place a large number of Jadelle implants each week. These clinics often have to make multiple orders, which can take a lot of time,” says Copland.

“This is why we are proposing to increase the number of Jadelle that clinics can order on PSO, as it will reduce how many orders need to be made and save these clinics time.”

The Government provided additional funding to Pharmac in June 2024 to fund new medicines and widen access to medicines that are already funded. The funding boost covers medicines for both cancer and non-cancer health conditions.

The consultation closes on 4pm on Friday 25 April. If the decision is approved, we expect these changes will be made from 1 July 2025.

Pharmac proposing to fund two brands of oestradiol patches

Source: PHARMAC

Pharmac is seeking feedback on a proposal to fund two brands of oestradiol patches for New Zealanders to use – Estradot, and Estradiol TDP Mylan.

If approved, Pharmac would fund both brands of oestradiol patches from 1 December 2025 and people could use either brand of patch, subject to availability. The public consultation opens on 27 March and closes on 22 April. 

In November 2024, Pharmac decided to fund Estradiol TDP Mylan oestradiol patches as the main funded brand to manage supply issues. When Pharmac notified the decision, we received a significant amount of feedback about the importance of having multiple brands of oestradiol patches available.

“We heard very clearly at the end of last year that a single brand of patch does not work well for everyone, and that we needed to have consulted more fully than we did. We are sorry for this and want to get it right this time.”

Since then, Pharmac has been working with people who use oestradiol patches, menopause specialists, doctors, nurses, and pharmacists to reflect their feedback in a new proposal to fund both Estradot and TDP Mylan patches.

“We want to thank everyone who has provided feedback on the need for more than one brand of oestradiol patch,” says Pharmac’s Manager of Pharmaceuticals, Adrienne Martin.

“We encourage everyone who uses oestradiol patches or who works with people who do, and anyone else with an interest in this issue, to take part in our public consultation.”

She noted, however, that there continue to be ongoing issues with the supply of Estradot.

“Internationally and in New Zealand there has been a large increase in demand for oestradiol patches over the last few years and we expect this to keep increasing. These increases have meant that the factory that makes Estradot cannot make enough to keep up with increasing demand.

“Through this proposal we have secured as much stock of Estradot as the supplier can provide but unfortunately the ongoing global supply issues mean there may be times when there’s not enough Estradot patches for everyone who wants to use them,” she says.

“The supplier of Estradiol TDP Mylan has assured Pharmac that it can produce enough patches to meet the demand in New Zealand. This is why our proposal is to have two brands funded. Pharmac also funds other oestradiol treatments, like oestradiol gel, which can, for some people, be used as an alternative.” 

Martin says all currently funded brands of oestradiol patches will continue to be funded as Pharmac works through this process.

New work-based learning model

Source: Tertiary Education Commission

Last updated 21 May 2025
Last updated 21 May 2025

Print

Share

The Minister for Vocational Education has announced the government’s decision to introduce an industry-led independent work-based learning model.
The Minister for Vocational Education has announced the government’s decision to introduce an industry-led independent work-based learning model.

The two key components of the independent model are:

Work-based learning is able to be offered by any provider that meets the government’s quality and funding requirements: institutes of technology and polytechnics (ITPs), private training establishments (PTEs) and wānanga. Providers will manage all aspects of an apprenticeship or traineeship, including the pastoral care for learners.
Industry Skills Boards will be established on 1 January 2026 to ensure the qualifications needed by employers across the country are available to all providers. 

Industry Skills Boards will be statutory standard-setting bodies, with majority industry governance. They will be responsible for developing qualifications, endorsing programmes and moderating assessments over key industry sectors. They will also have a workforce analysis function for their sectors, and provide investment advice to the Tertiary Education Commission (TEC).
The industry-led independent model was consulted on earlier this year, but has a modified transition phase, designed to give industry a greater role in the future of the work-based learning system. 
To enable the transition to this new model, Te Pūkenga’s work-based learning divisions, including their existing apprentices and trainees, will transfer to an Industry Skills Board for up to two years.  It is expected that during this period industry-led private training enterprises will be established to take over delivery from the work-based learning divisions, and ITPs and wānanga will also establish new work-based learning programmes.
Employers, apprentices and trainees will be able to continue to work with and enrol the same people they currently work with. Although there will be changes to the reporting lines for the work-based learning divisions in Te Pūkenga, courses and qualifications will continue to be delivered, and every effort will be made to ensure that training is not disrupted.
See more on Minister Simmonds’ work-based learning announcement.

Changes to the vocational education and training (VET) system

Source: Tertiary Education Commission

Last updated 21 May 2025
Last updated 21 May 2025

Print

Share

In December 2023, the Government announced its intention to disestablish Te Pūkenga | New Zealand Institute of Skills and Technology and Workforce Development Councils (WDCs).
In December 2023, the Government announced its intention to disestablish Te Pūkenga | New Zealand Institute of Skills and Technology and Workforce Development Councils (WDCs).

The Government plans to establish Industry Skills Boards (ISBs) to manage standards-setting and associated functions and will re-establish institutes of technology and polytechnics (ITPs) as either stand-alone or federated entities.
In December 2024, the Government agreed to introduce legislation that would:

disestablish Te Pūkenga
enable the establishment of ITPs as either stand-alone or federated entities
establish ISBs to manage standards-setting and associated functions.

Government decisions to be made in 2025 include:

details on the legislation to enable the changes
the future model for work-based learning
funding frameworks to support the new entities and delivery models
which ITPs will be stand-alone or federated entities
the number and coverage of ISBs.

More information
New work-based learning model
Consultation on Industry Skills Boards’ coverage (now closed)
Help establish Industry Skills Boards
Redesign of Vocational Education and Training System – Ministry of Education

Data Specification for Work-based – Data System Refresh Programme

Source: Tertiary Education Commission

Last updated 21 May 2025
Last updated 21 May 2025

Print

Share

This page provides information about the data required for reporting Work-based delivery (Actuals) on DXP Ngā Kete.
This page provides information about the data required for reporting Work-based delivery (Actuals) on DXP Ngā Kete.

Qualification and programme eligibility – final-year Fees Free

Source: Tertiary Education Commission

On this page:

Only qualifications and programmes at Levels 3 and above on the New Zealand Qualifications and Credentials Framework (NZQCF) are eligible. Eligible qualifications and programmes must be recognised by the New Zealand Qualifications Authority (NZQA) or Universities New Zealand and funded by the Tertiary Education Commission (TEC) from:

the Delivery at Levels 3–7 (non-degree) on the NZQCF and all industry training Fund (DQ3-7), or
the Delivery at Levels 7 (degree) to 10 on the NZQCF Fund (DQ7-10), or
grants under section 556 of the Education and Training Act 2020 for tertiary provision towards a qualification on the NZQCF at Levels 3 or above.

Provider-based qualifications
Eligible provider-based qualifications are TEC-funded and are equal to or greater than 0.5 equivalent full-time students (EFTS).
Work-based programmes
Eligible work-based programmes are TEC-funded programmes comprising at least 120 credits.
Qualifications and programmes that are not eligible for final-year Fees Free
The following are not eligible for final-year Fees Free:

school learning programmes and secondary tertiary programmes
certificates of proficiency
pathway qualifications
zero fee programmes
qualifications funded through the Youth Guarantee (YG) Fund, Māori and Pasifika Trades Training (MPTT), or the Refugee English Funds 
qualifications and programmes at Levels 1 or 2 on the NZQCF
provider-based qualifications that are less than 0.5 EFTS, or work-based programmes that are less than 120 credits.

Pathway qualifications
Pathway qualifications are qualifications that prepare learners to progress into further study and training by supporting them to meet minimum entry requirements and/or to develop the required skills for higher study. For the purposes of final-year Fees Free, this includes:

bridging qualifications, Certificates of University Preparation, Certificates in Study and Employment Pathways, and Level 3 Study and Career Preparation (except when primarily intended for career preparation).

Qualifications focussed mainly on subject-specific content, such as arts or science, and are mostly cross-credited towards a higher qualification are unlikely to be a pathway qualification.
Any qualification confirmed as a pathway qualification will be excluded for all learners. The exclusion is not able to take into account individual learner intentions.
View the list of pathway qualifications that are excluded from Fees Free:
Pathway qualifications (XLSX 26 KB)
To request to add or remove a qualification from the list of pathway qualifications excluded from Fees Free, contact customerservice@tec.govt.nz with the subject: (EDUMIS number) Final-year Fees Free – pathway qualifications. Please briefly outline how the qualification you wish to add/remove from the list does/doesn’t meet the definition of a pathway qualification.
Qualification completion date
The qualification completion date is defined as the date the learner has met the requirements to be awarded the qualification (whether an eligible provider-based qualification or work-based programme). This should align with what is recorded on the learner’s New Zealand Record of Achievement.
For provider-based study, TEOs must submit the qualification completion date as part of their SDR submission from August 2025.
TEOs already report work-based programme completion dates to NZQA, which NZQA provide to TEC.
Qualification and programme eligibility FAQs
Why must provider-based qualifications comprise at least 0.5 EFTS and work-based programmes at least 120 credits to be eligible?
Setting a minimum threshold mitigates the risk of learners using their Fees Free entitlement on small pieces of study or training. For example, a learner will not be able to unknowingly consume their entitlement on a very short programme of 0.2 EFTS.
Setting the eligibility criteria for provider-based qualifications at 0.5 EFTS or greater means that the large number of learners who complete qualifications at this level, and don’t go on to do further study or training, can access final-year Fees Free.
A work-based programme minimum of 120 credits gives assurance that the training programme has career benefit for the learner. It reduces the risk that learners will either use up their Fees Free entitlement on short training programmes directed by (and often entirely paid for by) their employers, or that employers will shift training costs onto learners.
Why aren’t Level 1 and 2 qualifications covered by Fees Free?
The Fees Free policy aligns eligibility with student support and government tuition subsidies.
Foundation programmes and qualifications (at NZQCF Levels 1 and 2) are excluded because provider-based Level 1 and 2 study is already fees-free, and learners shouldn’t have to use their Fees Free entitlement on courses and programmes intended to prepare them for tertiary education at Levels 3 and above.
Why do programmes and courses have to be recognised and funded to be available for Fees Free?
Fees Free was designed to help New Zealanders access high-quality tertiary education that provides skills for life and work. When a course or programme is both recognised by the NZQA or Universities New Zealand, and funded by the TEC, it means the course is of a high educational standard.
Are private training establishment (PTE) courses covered by Fees Free?
Yes, as long as the provider-based qualification or work-based programme meets the eligibility criteria.
What happens if a learner is enrolled in two qualifications at the same time?
For provider-based study, a learner enrolled in two qualifications at the same time will only receive Fees Free on completion of their first qualification. We’ll use the qualification completion date reported by TEOs to determine the first completed qualification.
For work-based learning, eligibility is based on the learner’s first programme completion (apprenticeship or training programme) rather than the qualifications that make up that programme, many of which will be under the 120-credit minimum.